Hyperlipidemia
Conditions
Keywords
Hyperlipidemia, Proteinuria, Diabetes Mellitus
Brief summary
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
Interventions
DRUGRosuvastatin
DRUGAtorvastatin
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* greater than or equal to 18 years of age * Hyperlipidemia * Urinary protein
Exclusion criteria
* Previous rosuvastatin treatment \< 6 months prior to Visit 1 * Statin intolerance * Severe hypertension * Diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Protein/Creatinine Ratio at Week 52 [LOCF] | Assessed at baseline and Week 52 (LOCF) | Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Albumin/Creatinine Ratio at Week 26 | Assessed at baseline and Week 26 | Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio. |
| Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | Assessed at baseline and Week 52 [LOCF] | Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio. |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | Assessed at baseline and Week 26 | The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value. |
| Change From Baseline in eGFR at Week 52 [LOCF] | Assessed at baseline and Week 52 [LOCF] | The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value. |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26. | baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52. | 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C | 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26 | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. ) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Urinary Protein/Creatinine Ratio at Week 26. | Assessed at baseline and Week 26 | Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio. |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | Baseline and 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | Baseline and 52 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.) |
Countries
Brazil, Bulgaria, Canada, Denmark, Germany, Hungary, Italy, Mexico, Romania, South Africa, United States
Participant flow
Recruitment details
797 patients entered the study with moderate proteinuria and hypercholesterolemia and were receiving stable treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) for 3 or more months prior to Visit 1. The study was conducted at 114 participating centers in 11 countries.
Pre-assignment details
237 patients \[pts\] completed the 8-week lead-in period and were randomized. The most common reasons for discontinuation during the lead in period included incorrect enrollment (466 pts), development of study-specific discontinuation criteria (41 pts), and voluntary discontinuation (29 pts). 189 patients completed the study.
Participants by arm
| Arm | Count |
|---|---|
| Rosuvastatin 10 mg | 70 |
| Rosuvastatin 40 mg | 87 |
| Atorvastatin 80 mg | 80 |
| Total | 237 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 7 | 7 | 7 |
| Overall Study | Incorrect enrollment | 2 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 1 | 2 |
| Overall Study | Pregnancy | 1 | 2 | 0 |
| Overall Study | Protocol Violation | 1 | 1 | 1 |
| Overall Study | Study specific discontinuation criteria | 0 | 0 | 1 |
| Overall Study | Visit 10 was performed earlier | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 5 | 6 | 2 |
Baseline characteristics
| Characteristic | Total | Atorvastatin 80 mg | Rosuvastatin 10 mg | Rosuvastatin 40 mg |
|---|---|---|---|---|
| Age, Customized 18 to 49 years | 120 Participants | 42 Participants | 34 Participants | 44 Participants |
| Age, Customized 50 to 64 years | 92 Participants | 30 Participants | 31 Participants | 31 Participants |
| Age, Customized >=65 years | 25 Participants | 8 Participants | 5 Participants | 12 Participants |
| Estimated glomerular filtration rate [eGFR] | 75.419 mL/min STANDARD_DEVIATION 29.6012 | 71.464 mL/min STANDARD_DEVIATION 30.0156 | 78.315 mL/min STANDARD_DEVIATION 28.0653 | 76.774 mL/min STANDARD_DEVIATION 30.3878 |
| Sex: Female, Male Female | 94 Participants | 31 Participants | 28 Participants | 35 Participants |
| Sex: Female, Male Male | 143 Participants | 49 Participants | 42 Participants | 52 Participants |
| Urine albumin/creatinine ratio | 1091.263 mg/g STANDARD_DEVIATION 775.1889 | 1069.103 mg/g STANDARD_DEVIATION 720.8011 | 1023.165 mg/g STANDARD_DEVIATION 720.0251 | 1167.368 mg/g STANDARD_DEVIATION 865.4584 |
| Urine protein/creatinine ratio | 1416.023 mg/g STANDARD_DEVIATION 975.7636 | 1439.720 mg/g STANDARD_DEVIATION 991.2295 | 1301.163 mg/g STANDARD_DEVIATION 832.7398 | 1487.131 mg/g STANDARD_DEVIATION 1068.0642 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 15 / 69 | 16 / 87 | 17 / 80 |
| serious Total, serious adverse events | 10 / 69 | 6 / 87 | 5 / 80 |
Outcome results
Primary
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at baseline and Week 52 (LOCF)
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10 mg | Urinary Protein/Creatinine Ratio at Week 52 [LOCF] | 0.938 ratio |
| Rosuvastatin 40 mg | Urinary Protein/Creatinine Ratio at Week 52 [LOCF] | 1.082 ratio |
| Atorvastatin 80 mg | Urinary Protein/Creatinine Ratio at Week 52 [LOCF] | 0.759 ratio |
Secondary
Change From Baseline in eGFR at Week 52 [LOCF]
The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value.
Time frame: Assessed at baseline and Week 52 [LOCF]
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin 10 mg | Change From Baseline in eGFR at Week 52 [LOCF] | -2.71 mL/min | Standard Deviation 13.083 |
| Rosuvastatin 40 mg | Change From Baseline in eGFR at Week 52 [LOCF] | -3.30 mL/min | Standard Deviation 12.325 |
| Atorvastatin 80 mg | Change From Baseline in eGFR at Week 52 [LOCF] | -1.74 mL/min | Standard Deviation 13.964 |
Secondary
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.
Time frame: Assessed at baseline and Week 26
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin 10 mg | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | 1.39 mL/min | Standard Deviation 15.431 |
| Rosuvastatin 40 mg | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | -3.41 mL/min | Standard Deviation 13.228 |
| Atorvastatin 80 mg | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | -1.61 mL/min | Standard Deviation 9.494 |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26 | 0.13029 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26 | 0.17554 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26 | 0.14191 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52 | 0.11047 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52 | 0.07751 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52 | 0.08580 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.02907 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | -0.09476 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | -0.00160 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | -0.15415 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | 0.10486 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | -0.06121 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26 | 0.06098 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26 | -0.03181 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26 | 0.03861 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52 | -0.11217 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52 | 0.11006 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52 | -0.03932 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.04858 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | -0.05535 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.02023 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | -0.20805 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | 0.18299 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | -0.07681 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26 | 0.06029 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26 | -0.08151 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26 | 0.02283 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52 | -0.19532 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52 | 0.14967 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52 | -0.09001 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.08263 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | -0.06860 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.04337 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | -0.23887 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.17170 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | -0.10817 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.08194 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | -0.06576 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.04477 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | -0.23597 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | 0.19933 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | -0.10205 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG | -0.12643 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG | 0.00486 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG | -0.08301 Correlation coefficient |
Secondary
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26 | 0.04160 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26 | 0.00531 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26 | 0.03430 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26 | 0.01684 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26 | 0.01755 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26 | 0.01758 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52 | 0.14080 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52 | 0.02750 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52 | 0.09472 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26 | 0.02679 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26 | -0.07603 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26 | -0.00171 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52 | -0.15731 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52 | 0.15368 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52 | -0.06310 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26 | 0.06641 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26 | -0.07964 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26 | 0.02900 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52 | -0.15721 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52 | 0.16110 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52 | -0.05794 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26 | 0.16499 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26 | 0.02609 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26 | 0.15049 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.20021 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.12953 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.18870 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.10258 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.13505 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.11103 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | 0.08108 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | -0.16753 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | 0.00479 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26 | 0.18720 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26 | 0.16167 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26 | 0.18717 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 0.21082 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | -0.04379 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 0.14085 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26 | 0.23547 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26 | 0.25043 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26 | 0.25208 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.17479 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.18677 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.18203 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26 | 0.14783 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26 | 0.21561 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26 | 0.16899 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52 | 0.20285 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52 | -0.13565 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52 | 0.12568 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.05037 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.09779 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.05936 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | 0.10365 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | -0.24717 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | 0.01386 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26 | 0.16080 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26 | 0.17150 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26 | 0.16578 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | 0.24107 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | -0.08640 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | 0.16525 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.04955 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.02740 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.03798 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.11997 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | -0.21073 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.03955 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26 | 0.18188 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26 | 0.17503 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26 | 0.18566 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52 | 0.23734 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52 | 0.01311 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52 | 0.17958 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.02506 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.02201 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.01860 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | 0.08954 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | -0.20870 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | 0.01926 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26 | 0.11526 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26 | -0.06890 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26 | 0.07248 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.21730 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.21151 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.21477 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.19626 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.09835 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.18349 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.10698 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.13814 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.11414 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | 0.05859 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | -0.12938 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | -0.00540 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 0.18473 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | -0.02690 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 0.12496 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26 | 0.12595 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26 | 0.05628 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26 | 0.13754 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26 | 0.18504 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26 | 0.17259 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26 | 0.19146 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.20346 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.18041 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.20818 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26 | 0.18055 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26 | 0.24987 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26 | 0.22094 Correlation coefficient |
Secondary
Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C | 0.16868 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C | -0.09428 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C | 0.10679 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.06383 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.12687 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.07462 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | 0.05881 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | -0.20262 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | -0.01340 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26 | 0.14302 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26 | 0.24393 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26 | 0.17632 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | 0.20386 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | -0.04698 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | 0.14495 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.06794 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.05410 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.05465 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.07188 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | -0.16669 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.00955 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. )
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26 | 0.16206 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26 | 0.20032 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26 | 0.17628 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.04652 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.06344 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.04149 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | 0.03957 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | -0.17644 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | -0.01549 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.20659 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.23989 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.21728 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26. | 0.17601 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26. | 0.21701 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26. | 0.19643 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52. | 0.20462 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52. | 0.03480 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52. | 0.16077 Correlation coefficient |
Secondary
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26 | 0.15348 Correlation coefficient |
| Rosuvastatin 40 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26 | -0.06049 Correlation coefficient |
| Atorvastatin 80 mg | Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26 | 0.10089 Correlation coefficient |
Secondary
Urinary Albumin/Creatinine Ratio at Week 26
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at baseline and Week 26
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10 mg | Urinary Albumin/Creatinine Ratio at Week 26 | 0.850 ratio |
| Rosuvastatin 40 mg | Urinary Albumin/Creatinine Ratio at Week 26 | 0.946 ratio |
| Atorvastatin 80 mg | Urinary Albumin/Creatinine Ratio at Week 26 | 0.731 ratio |
Secondary
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at baseline and Week 52 [LOCF]
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10 mg | Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 0.879 ratio |
| Rosuvastatin 40 mg | Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 0.967 ratio |
| Atorvastatin 80 mg | Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 0.719 ratio |
Secondary
Urinary Protein/Creatinine Ratio at Week 26.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at baseline and Week 26
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10 mg | Urinary Protein/Creatinine Ratio at Week 26. | 0.932 ratio |
| Rosuvastatin 40 mg | Urinary Protein/Creatinine Ratio at Week 26. | 1.057 ratio |
| Atorvastatin 80 mg | Urinary Protein/Creatinine Ratio at Week 26. | 0.762 ratio |